Menu Search
Equities

Basilea Pharmaceutica AG Allschwil

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0QNA:LSE

Basilea Pharmaceutica AG Allschwil

Actions
  • Price (CHF)56.61
  • Today's Change-0.994 / -1.73%
  • Shares traded24.51k
  • 1 Year change+38.23%
  • Beta0.5444
Data delayed at least 20 minutes, as of Feb 06 2026 17:39 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

  • Revenue in CHF (TTM)236.21m
  • Net income in CHF72.66m
  • Incorporated2002
  • Employees180.00
  • Location
    Basilea Pharmaceutica AG AllschwilHegenheimermattweg 167bALLSCHWIL 4123SwitzerlandCHE
  • Phone+41 616061111
  • Fax+41 616061112
  • Websitehttps://www.basilea.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.